Last-Resort cell therapy targets rare cancer in single patient
NCT ID NCT06789081
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests a made-to-order cell therapy called GCAR1 in one person with advanced alveolar soft part sarcoma that has spread and has no standard treatments left. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called GPNMB. The main goal is to see if the tumor shrinks or disappears on scans taken 4 to 6 weeks after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
Conditions
Explore the condition pages connected to this study.